Editas takes licence to CRISPR technology amid patent battle


Editas Medicine, a US genome-editing company, has taken a licence to intellectual property relating to CRISPR technologies for human therapeutics, amid a continuing CRISPR patent battle.

Editas Medicine, CRISPR, human therapeutics, Broad Institute of MIT and Harvard, MIT, University of California